RISK OF DEATH AFTER PACLITAXEL EXPOSURE DURING FEMOROPOPLITEAL ARTERY ANGIOPLASTY – NARRATIVE REVIEW
Paclitaxel molecule has been on the market since 1991 and is indicated for the treatment of multiple neoplasms. Since 2012 has been used in endovascular devices for the treatment of peripheral artery disease and have become a mainstay in the treatment of symptomatic femoro-popliteal lesions, in...
| Автори: | , , , , , , |
|---|---|
| Формат: | Стаття |
| Мова: | Portuguese |
| Опубліковано: |
Sociedade Portuguesa de Angiologia e Cirurgia Vascular
2022-03-01
|
| Серія: | Angiologia e Cirurgia Vascular |
| Предмети: | |
| Онлайн доступ: | https://acvjournal.com/index.php/acv/article/view/436 |